NewAmsterdam Pharma Company N.V.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving NewAmsterdam Pharma Company N.V. now
Current reporting with the operating signal separated from the noise.
NewAmsterdam Pharma Company N.V. (NAMS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
The story matters when it changes NewAmsterdam Pharma Company N.V.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Here’s Why NewAmsterdam Pharma Company N.V. (NAMS) Surged 23% in Q4
The story matters when it changes NewAmsterdam Pharma Company N.V.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.NewAmsterdam Pharma Company N.V. (NAMS) Shares Spiked by 57% in Q3
Investors are testing whether NewAmsterdam Pharma Company N.V.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.NewAmsterdam Pharma Company N.V. (NAMS) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
The story matters when it changes NewAmsterdam Pharma Company N.V.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.NewAmsterdam Pharma Company N.V. (NAMS) Expected to Beat Earnings Estimates: Should You Buy?
Investors are testing whether NewAmsterdam Pharma Company N.V.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Tops Revenue Estimates
Investors are testing whether NewAmsterdam Pharma Company N.V.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.NewAmsterdam Pharma Company N.V.
The story matters when it changes NewAmsterdam Pharma Company N.V.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Latest NAMS filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
NewAmsterdam Pharma Company N.V., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →